<DOC>
	<DOC>NCT01194193</DOC>
	<brief_summary>To investigate the safety and tolerability of AZD8055 intermittent dosing schedules when given orally to patients with advanced solid malignancies and lymphomas. Two intermittent dosing schedules will be explored with increasing doses until a maximum tolerated dose is determined for each schedule.</brief_summary>
	<brief_title>Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Histological or cytological confirmation of an advanced solid malignant tumour or lymphoma which is refactory to standard therapies or for which no standard therapy exists, patients with measurable or nonmeasurable disease (according to RECIST criteria) WHO performance status 02 Evidence of postmenopausal status or negative urine/serum pregnancy test for premenopausal female patients Patients with severe laboratory abnormalities for haematology, liver or renal function. Also treatment with any haemopoietic growth factors are not allowed within two weeks from first dose of study drug. Any investigational agents or study drugs from a previous clinical study within 30 days, any other chemotherapy, immunotherapy or anticancer agents within 3 weeks of the first dose of study treatment Patients with severe cardiac condition of ischemia, impaired ventricular function and arrhythmias, evidence of severe or uncontrolled systemic or current unstable or uncompensated respiratory or cardiac conditions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Advanced solid tumours</keyword>
	<keyword>lymphomas</keyword>
	<keyword>dose escalation</keyword>
	<keyword>preliminary anti-tumour activity</keyword>
	<keyword>Tor kinase inhibitor</keyword>
	<keyword>oral administration</keyword>
	<keyword>intermittent dosing</keyword>
</DOC>